Search results for "From ACP Internist"
ADA updates diabetes standards of care for 2023
The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.
https://diabetes.acponline.org/archives/2023/01/13/5.htm
13 Jan 2023
USPSTF lowers age for starting diabetes screening from 40 to 35 years
Primary care clinicians should screen all overweight or obese adults ages 35 to 70 years for diabetes and prediabetes and should offer interventions for those with either condition, the U.S. Preventive Services Task Force (USPSTF) recently recommended.
https://diabetes.acponline.org/archives/2021/09/10/6.htm
10 Sep 2021
Racial, economic disparities found in use of SGLT2 inhibitors
Although use of sodium-glucose cotransporter-2 (SGLT2) inhibitors rose overall between 2015 and 2019, patients who were Black, Asian, female, or with lower household income had lower rates of prescriptions for the drug class than others with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/8.htm
14 May 2021
SGLT-2 inhibitors not associated with increased risk for severe UTIs
An accompanying editorial said that while the study's finding is reassuring, it should be considered with caution, especially since high-risk patients and those with previous urinary tract infections (UTIs) were excluded.
https://diabetes.acponline.org/archives/2019/08/09/7.htm
9 Aug 2019
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
https://diabetes.acponline.org/archives/2022/10/14/8.htm
14 Oct 2022
SGLT2 inhibitors associated with rare, life-threatening necrotizing genital infections
In the past six years, nearly three times as many cases of Fournier gangrene were reported in patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors as in the past 35 years in patients taking other antiglycemic agents.
https://diabetes.acponline.org/archives/2019/05/10/11.htm
10 May 2019
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023
Expert panel recommends SGLT2 inhibitor or GLP-1 receptor agonist for patients with type 2 diabetes and CVD
The American College of Cardiology's new decision pathway also calls for repeated HbA1c screening and detailed clinician-patient risk discussions for patients with cardiovascular disease (CVD) who are diagnosed with type 2 diabetes.
https://diabetes.acponline.org/archives/2018/12/14/9.htm
14 Dec 2018
Newer, older insulin formulations may offer similar glucose-lowering effects
The findings may help inform decisions about insulin therapy for patients with type 2 diabetes, for example, when minimizing weight gain or nocturnal hypoglycemia is a priority.
https://diabetes.acponline.org/archives/2018/07/13/8.htm
13 Jul 2018
ACP recommends less intensive glucose control in most cases of type 2 diabetes
The evidence-based guidance statement from ACP calls for personalized goals and an HbA1c target between 7% and 8% for most patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2018/03/09/6.htm
9 Mar 2018